99 related articles for article (PubMed ID: 11145172)
1. Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats.
Oku A; Ueta K; Arakawa K; Kano-Ishihara T; Matsumoto M; Adachi T; Yasuda K; Tsuda K; Saito A
Biol Pharm Bull; 2000 Dec; 23(12):1434-7. PubMed ID: 11145172
[TBL] [Abstract][Full Text] [Related]
2. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.
Adachi T; Yasuda K; Okamoto Y; Shihara N; Oku A; Ueta K; Kitamura K; Saito A; Iwakura I; Yamada Y; Yano H; Seino Y; Tsuda K
Metabolism; 2000 Aug; 49(8):990-5. PubMed ID: 10954015
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats.
Oku A; Ueta K; Nawano M; Arakawa K; Kano-Ishihara T; Matsumoto M; Saito A; Tsujihara K; Anai M; Asano T
Eur J Pharmacol; 2000 Mar; 391(1-2):183-92. PubMed ID: 10720650
[TBL] [Abstract][Full Text] [Related]
4. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
Arakawa K; Ishihara T; Oku A; Nawano M; Ueta K; Kitamura K; Matsumoto M; Saito A
Br J Pharmacol; 2001 Jan; 132(2):578-86. PubMed ID: 11159708
[TBL] [Abstract][Full Text] [Related]
5. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
Oku A; Ueta K; Arakawa K; Ishihara T; Nawano M; Kuronuma Y; Matsumoto M; Saito A; Tsujihara K; Anai M; Asano T; Kanai Y; Endou H
Diabetes; 1999 Sep; 48(9):1794-800. PubMed ID: 10480610
[TBL] [Abstract][Full Text] [Related]
6. Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats.
Oku A; Ueta K; Arakawa K; Kano-Ishihara T; Matsumoto T; Adachi T; Yasuda K; Tsuda K; Ikezawa K; Saito A
Jpn J Pharmacol; 2000 Nov; 84(3):351-4. PubMed ID: 11138738
[TBL] [Abstract][Full Text] [Related]
7. Pyrazole-O-glucosides as novel Na(+)-glucose cotransporter (SGLT) inhibitors.
Ohsumi K; Matsueda H; Hatanaka T; Hirama R; Umemura T; Oonuki A; Ishida N; Kageyama Y; Maezono K; Kondo N
Bioorg Med Chem Lett; 2003 Jul; 13(14):2269-72. PubMed ID: 12824015
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats.
Nunoi K; Yasuda K; Adachi T; Okamoto Y; Shihara N; Uno M; Tamon A; Suzuki N; Oku A; Tsuda K
Clin Exp Pharmacol Physiol; 2002; 29(5-6):386-90. PubMed ID: 12010180
[TBL] [Abstract][Full Text] [Related]
9. Reduction of renal transport maximum for glucose by inhibition of NA(+)-glucose cotransporter suppresses blood glucose elevation in dogs.
Ueta K; Yoneda H; Oku A; Nishiyama S; Saito A; Arakawa K
Biol Pharm Bull; 2006 Jan; 29(1):114-8. PubMed ID: 16394522
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
[TBL] [Abstract][Full Text] [Related]
11. Normalization of cytoplasmic calcium response in pancreatic beta-cells of spontaneously diabetic GK rat by the treatment with T-1095, a specific inhibitor of renal Na+-glucose co-transporters.
Yasuda K; Okamoto Y; Nunoi K; Adachi T; Shihara N; Tamon A; Suzuki N; Mukai E; Fujimoto S; Oku A; Tsuda K; Seino Y
Horm Metab Res; 2002 Apr; 34(4):217-21. PubMed ID: 11987033
[TBL] [Abstract][Full Text] [Related]
12. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept.
Tsujihara K; Hongu M; Saito K; Inamasu M; Arakawa K; Oku A; Matsumoto M
Chem Pharm Bull (Tokyo); 1996 Jun; 44(6):1174-80. PubMed ID: 8814948
[TBL] [Abstract][Full Text] [Related]
13. Antihyperglycemic effect of hesperetin, a citrus flavonoid, extenuates hyperglycemia and exploring the potential role in antioxidant and antihyperlipidemic in streptozotocin-induced diabetic rats.
Jayaraman R; Subramani S; Sheik Abdullah SH; Udaiyar M
Biomed Pharmacother; 2018 Jan; 97():98-106. PubMed ID: 29080465
[TBL] [Abstract][Full Text] [Related]
14. Antihyperglycemic effect of catalpol in streptozotocin-induced diabetic rats.
Huang WJ; Niu HS; Lin MH; Cheng JT; Hsu FL
J Nat Prod; 2010 Jun; 73(6):1170-2. PubMed ID: 20518543
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats.
Ueta K; Ishihara T; Matsumoto Y; Oku A; Nawano M; Fujita T; Saito A; Arakawa K
Life Sci; 2005 Apr; 76(23):2655-68. PubMed ID: 15792833
[TBL] [Abstract][Full Text] [Related]
16. Increase of beta-endorphin secretion by syringin, an active principle of Eleutherococcus senticosus, to produce antihyperglycemic action in type 1-like diabetic rats.
Niu HS; Hsu FL; Liu IM; Cheng JT
Horm Metab Res; 2007 Dec; 39(12):894-8. PubMed ID: 18075969
[TBL] [Abstract][Full Text] [Related]
17. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
18. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
Fujimori Y; Katsuno K; Ojima K; Nakashima I; Nakano S; Ishikawa-Takemura Y; Kusama H; Isaji M
Eur J Pharmacol; 2009 May; 609(1-3):148-54. PubMed ID: 19281809
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
[TBL] [Abstract][Full Text] [Related]
20. Antihyperglycemic action of isoferulic acid in streptozotocin-induced diabetic rats.
Liu IM; Hsu FL; Chen CF; Cheng JT
Br J Pharmacol; 2000 Feb; 129(4):631-6. PubMed ID: 10683186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
